M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Illumina Faces Proxy Battle Over Grail Acquisition
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Amazon Closes One Medical Acquisition but FTC Intervention Looms
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
Lab Companies See Massive Layoffs and Restructuring
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.